Amir Hossein Faghfouri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Amir Hossein Faghfouri has a total of 125 co-authors. Here are the top co-authors by number of shared publications:
- Elnaz Faghfuri
Digestive Disease Research Center, Ardabil University of Medical Sciences, Ardabil, Iran
6 shared publications - Vali Musazadeh
Student Research Committee, School of Public Health, Iran University of Medical Sciences, Tehran, Iran
6 shared publications Amir Hossein Moridpour
Student research committee, Department of Nutritional Sciences, School of Nutrition Sciences and Food Technology, Kermanshah University of Medical Sciences, Kermanshah, Iran
5 shared publications- Beitullah Alipour
Department of Community Nutrition, Faculty of nutrition and food sciences, Tabriz University of Medical Sciences, Tabriz, Iran
5 shared publications Zeynab Kavyani
Student Research Committee, Department of Clinical Nutrition and Dietetics, Faculty of Nutrition Sciences and Food Technology, National Nutrition & Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5 shared publicationsAlireza Khabbazi
Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
4 shared publications
Latest Publications
- Open Access
- 19 August 2026
- Published by Springer Nature in BMC Pediatrics
- Vol. 26 (1)
Effectiveness of a home-based nutritional intervention program on anthropometric indices of preschool children with overweight and obesity: a cluster randomized controlled clinical trial
- 19 August 2026
- Published by Springer Nature in BMC Pediatrics
- Vol. 26 (1)
Open AccessEffectiveness of a home-based nutritional intervention program on anthropometric indices of preschool children with overweight and obesity: a cluster randomized controlled clinical trial
- 10 April 2026
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 62 (5) , 678-696
Effects of Probiotic and Synbiotic Supplementation on Metabolic and Hepatic Outcomes in Children and Adolescents With Obesity, Including Those With Obesity‐Related Metabolic Dysfunction–Associated Steatotic Liver Disease: A Systematic Review and Meta‐Analysis
Aim: This systematic review and meta‐analysis evaluated the effects of probiotic and synbiotic supplementation on metabolic and hepatic outcomes in children and adolescents with obesity, including those with obesity‐related metabolic dysfunction–associated steatotic liver disease (MASLD). Methods: A comprehensive literature search of PubMed, Scopus and Web of Science was conducted up to September 2025. Randomised controlled trials (RCTs) investigating probiotic or synbiotic supplementation in paediatric populations with obesity or MASLD were included. Data were pooled using a random‐effects model, and the Cochrane Risk of Bias tool and GRADE framework were used for quality assessment. Results: Thirteen RCTs ( n = 848) were included. Pooled analyses demonstrated significant reductions in total cholesterol (WMD: −6.40 mg/dL, 95% CI: −8.78, −4.01), LDL‐C (WMD: −2.68 mg/dL, 95% CI: −4.85, −0.50) and alanine aminotransferase (ALT) (WMD: −6.15 U/L, 95% CI: −10.14, −2.16). No significant improvements were observed in BMI z ‐score, waist circumference, triglycerides, HDL‐C or fasting blood sugar. A significant increase in HOMA‐IR was found (WMD: 0.68, 95% CI: 0.53, 0.83). Evidence certainty was high for lipid outcomes but low or very low for most other measures. Conclusions: Despite these mixed results, substantial heterogeneity and limited evidence quality underscore the need for well‐designed, strain‐specific trials. Probiotic and synbiotic supplementation show promise for specific metabolic outcomes in paediatric populations, though caution is warranted regarding glucose homeostasis, and personalised approaches should be considered in clinical practice.
- 10 April 2026
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 62 (5) , 678-696
Effects of Probiotic and Synbiotic Supplementation on Metabolic and Hepatic Outcomes in Children and Adolescents With Obesity, Including Those With Obesity‐Related Metabolic Dysfunction–Associated Steatotic Liver Disease: A Systematic Review and Meta‐Analysis
Aim: This systematic review and meta‐analysis evaluated the effects of probiotic and synbiotic supplementation on metabolic and hepatic outcomes in children and adolescents with obesity, including those with obesity‐related metabolic dysfunction–associated steatotic liver disease (MASLD). Methods: A comprehensive literature search of PubMed, Scopus and Web of Science was conducted up to September 2025. Randomised controlled trials (RCTs) investigating probiotic or synbiotic supplementation in paediatric populations with obesity or MASLD were included. Data were pooled using a random‐effects model, and the Cochrane Risk of Bias tool and GRADE framework were used for quality assessment. Results: Thirteen RCTs ( n = 848) were included. Pooled analyses demonstrated significant reductions in total cholesterol (WMD: −6.40 mg/dL, 95% CI: −8.78, −4.01), LDL‐C (WMD: −2.68 mg/dL, 95% CI: −4.85, −0.50) and alanine aminotransferase (ALT) (WMD: −6.15 U/L, 95% CI: −10.14, −2.16). No significant improvements were observed in BMI z ‐score, waist circumference, triglycerides, HDL‐C or fasting blood sugar. A significant increase in HOMA‐IR was found (WMD: 0.68, 95% CI: 0.53, 0.83). Evidence certainty was high for lipid outcomes but low or very low for most other measures. Conclusions: Despite these mixed results, substantial heterogeneity and limited evidence quality underscore the need for well‐designed, strain‐specific trials. Probiotic and synbiotic supplementation show promise for specific metabolic outcomes in paediatric populations, though caution is warranted regarding glucose homeostasis, and personalised approaches should be considered in clinical practice.
- Open Access
- 7 November 2025
- Published by Cambridge University Press (CUP) in British Journal of Nutrition
- Vol. 135 (1) , 42-62
Effect of vitamin E on cardiometabolic factors in paediatric metabolic dysfunction-associated steatotic liver disease: a systematic review with meta-analysis
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a serious disease and increasingly prevalent in children. MASLD is associated with health consequences such as type 2 diabetes and CVD. While vitamin E is a potent antioxidant that has been proposed to improve liver function and cardiometabolic health including liver markers, lipid profile, glycaemic control and anthropometric measurements. A comprehensive search was conducted up to March 2025. Data on anthropometric measures, liver enzymes (alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ -glutamyl transferase (GGT)), glycaemic indices (fasting blood sugar (FBS), insulin, homeostatic model assessment for insulin resistance (HOMA-IR)), lipid profiles (total cholesterol (TC), TAG, LDL-cholesterol, HDL-cholesterol) and serum vitamin E levels were extracted. Statistical analyses were performed using a random-effects model. Eleven randomised controlled trials involving 665 participants were included in this study. Vitamin E significantly reduced ALT (weighted mean difference (WMD) = −5·23 U/L; 95 % CI: −7·72, −2·75; P < 0·001) and AST (WMD = −3·00 U/L; 95 % CI: −4·59, −1·41; P < 0·001), reflecting improved liver function. It also decreased TC (WMD = −5·77 mg/dl; 95 % CI: −11·46, −0·09; P = 0·04) and HOMA-IR (WMD = −0·82; 95 % CI: −1·28, −0·37; P < 0·001), while significantly increasing serum vitamin E levels (WMD = 9·16 mg/l; 95 % CI: 3·29, 15·03; P = 0·002). No significant changes were observed in the BMI, GGT, FBS, insulin, LDL-cholesterol, HDL-cholesterol or TAG levels. Vitamin E supplementation in paediatric MASLD appears to favourably influence key liver enzymes such as ALT, AST and certain metabolic factors including TC, and HOMA-IR levels, supporting its potential role as adjunctive therapy.
- 7 November 2025
- Published by Cambridge University Press (CUP) in British Journal of Nutrition
- Vol. 135 (1) , 42-62
Open AccessEffect of vitamin E on cardiometabolic factors in paediatric metabolic dysfunction-associated steatotic liver disease: a systematic review with meta-analysis
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a serious disease and increasingly prevalent in children. MASLD is associated with health consequences such as type 2 diabetes and CVD. While vitamin E is a potent antioxidant that has been proposed to improve liver function and cardiometabolic health including liver markers, lipid profile, glycaemic control and anthropometric measurements. A comprehensive search was conducted up to March 2025. Data on anthropometric measures, liver enzymes (alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ -glutamyl transferase (GGT)), glycaemic indices (fasting blood sugar (FBS), insulin, homeostatic model assessment for insulin resistance (HOMA-IR)), lipid profiles (total cholesterol (TC), TAG, LDL-cholesterol, HDL-cholesterol) and serum vitamin E levels were extracted. Statistical analyses were performed using a random-effects model. Eleven randomised controlled trials involving 665 participants were included in this study. Vitamin E significantly reduced ALT (weighted mean difference (WMD) = −5·23 U/L; 95 % CI: −7·72, −2·75; P < 0·001) and AST (WMD = −3·00 U/L; 95 % CI: −4·59, −1·41; P < 0·001), reflecting improved liver function. It also decreased TC (WMD = −5·77 mg/dl; 95 % CI: −11·46, −0·09; P = 0·04) and HOMA-IR (WMD = −0·82; 95 % CI: −1·28, −0·37; P < 0·001), while significantly increasing serum vitamin E levels (WMD = 9·16 mg/l; 95 % CI: 3·29, 15·03; P = 0·002). No significant changes were observed in the BMI, GGT, FBS, insulin, LDL-cholesterol, HDL-cholesterol or TAG levels. Vitamin E supplementation in paediatric MASLD appears to favourably influence key liver enzymes such as ALT, AST and certain metabolic factors including TC, and HOMA-IR levels, supporting its potential role as adjunctive therapy.
- 28 May 2025
- Published by Wiley in Obesity Reviews
- Vol. 26 (10) , e13946
Efficacy and Safety of Pharmacological Interventions in Managing Cardiometabolic Risk Factors in Youth Living with Overweight and Obesity: A Systematic Review and Network Meta‐Analysis
Background: Obesity has become a growing global health concern among young people. This meta‐analysis seeks to systematically assess the efficacy and safety of pharmaceutical interventions in improving body weight, body mass index (BMI), waist circumference (WC), diastolic blood pressure (DBP), fasting blood glucose (FBG), and lipid profiles, planned prior to data collection.Methods: We conducted a comprehensive literature search on PubMed, Scopus, Embase, Web of Science, and the Cochrane Library, covering studies published up to September 2024. Randomized clinical trials (RCTs) were included if they reported efficacy of weight‐loss medications in youth populations aged 2–20 years. Direct and indirect evidence were synthesized using a frequentist framework.Results: Pooled analysis on 30 RCTs showed that high dose phentermine/topiramate was more effective in reducing weight (MD: −15.8 kg; 95%CI: −19.17 to −12.43), BMI (MD = −5.35 kg/m2; 95% CI: −8.03, −2.67), WC (MD = −7.69 cm; 95% CI: −10.19, −5.18), and BMI percentile (MD: ‐20.25; 95%CI: −24.82 to 95% CI: −20.38 to −1.62) compared to placebo. Orlistat (MD = −1.81 mmHg; 95% CI: −2.94, −0.68), metformin (MD: −0.14 unit; 95%CI: −0.23 to −0.04), liraglutide (MD: −11.00 mg/dL; 95% CI: −20.38 to −1.62) were more effective in improving DBP, BMI‐z score, and FBG, respectively. Lipid profile and SBP were not affected by studied drugs.Conclusion: High‐ and moderate‐dose phentermine/topiramate was more effective than a placebo in reducing anthropometric measures in youth living with overweight and obesity. Liraglutide and metformin result in a significant reduction in FBG levels compared to placebo.
- 28 May 2025
- Published by Wiley in Obesity Reviews
- Vol. 26 (10) , e13946
Efficacy and Safety of Pharmacological Interventions in Managing Cardiometabolic Risk Factors in Youth Living with Overweight and Obesity: A Systematic Review and Network Meta‐Analysis
Background: Obesity has become a growing global health concern among young people. This meta‐analysis seeks to systematically assess the efficacy and safety of pharmaceutical interventions in improving body weight, body mass index (BMI), waist circumference (WC), diastolic blood pressure (DBP), fasting blood glucose (FBG), and lipid profiles, planned prior to data collection.Methods: We conducted a comprehensive literature search on PubMed, Scopus, Embase, Web of Science, and the Cochrane Library, covering studies published up to September 2024. Randomized clinical trials (RCTs) were included if they reported efficacy of weight‐loss medications in youth populations aged 2–20 years. Direct and indirect evidence were synthesized using a frequentist framework.Results: Pooled analysis on 30 RCTs showed that high dose phentermine/topiramate was more effective in reducing weight (MD: −15.8 kg; 95%CI: −19.17 to −12.43), BMI (MD = −5.35 kg/m2; 95% CI: −8.03, −2.67), WC (MD = −7.69 cm; 95% CI: −10.19, −5.18), and BMI percentile (MD: ‐20.25; 95%CI: −24.82 to 95% CI: −20.38 to −1.62) compared to placebo. Orlistat (MD = −1.81 mmHg; 95% CI: −2.94, −0.68), metformin (MD: −0.14 unit; 95%CI: −0.23 to −0.04), liraglutide (MD: −11.00 mg/dL; 95% CI: −20.38 to −1.62) were more effective in improving DBP, BMI‐z score, and FBG, respectively. Lipid profile and SBP were not affected by studied drugs.Conclusion: High‐ and moderate‐dose phentermine/topiramate was more effective than a placebo in reducing anthropometric measures in youth living with overweight and obesity. Liraglutide and metformin result in a significant reduction in FBG levels compared to placebo.
- 28 December 2024
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 24 (1) , 32
Effectiveness of different gums on modulating of glycemic indices in adults: a systematic review and meta-analysis
Background Functional foods have been widely used as the anti-diabetic agents worldwide. Existing studies presented conflicting results of anti-hyperglycemic properties of gums. This systematic review and meta-analysis study evaluated the existing trials and determined the efficacy of different gums on glycemic indices. Method Systematic search was performed on four main databases (PubMed, Scopus, Embase, Web of Science) by November 2023 using medical subject headings. The meta-analyses were conducted on the findings of the studies of guar gum supplementation on glycemic indices including fasting blood glucose (FBG) and HbA1c (hemoglobinA1c) and systematic review studies include the effect of xanthan gum, arabic gum, bitter almond gum, flaxseed gum, oat gum, gellan gum, locust been gum, tragacanth gum, and karaya gum on fasting plasma insulin, postprandial plasma glucose, HbA1c and Homeostatic Model Assessment for Insulin Resistance (HOMA – IR). Results Totally, 42 studies were included in this systematic review. Regarding guar gum, xanthan gum, and Arabic gum, most of included studies in our investigation showed that guar gum can be considered as an anti-hyperglycemic agent. Results on other types of gums including bitter almond gum, flaxseed gum, oat gum, gellan gum, locust been gum, tragacanth gum, and karaya gum are limited and exact interpretation cannot be obtained. In meta-analysis on 17 studies of guar gum, it was identified guar gum had a non-significant decrease of 3.02 mg/dl (Mean difference: -3.02, CI 95%: -7.60, 1.56) on the fasting glucose and 0.23 (Mean difference: -0.23, CI 95%: -0.63, 0.17) on HbA1c. Conclusion Modification of food processing using gums may be a promising strategy to help modulate glycemic indices. More studies with larger sample size are needed, both with acute and long-term interventions to clarify this issue.
- 28 December 2024
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 24 (1) , 32
Effectiveness of different gums on modulating of glycemic indices in adults: a systematic review and meta-analysis
Background Functional foods have been widely used as the anti-diabetic agents worldwide. Existing studies presented conflicting results of anti-hyperglycemic properties of gums. This systematic review and meta-analysis study evaluated the existing trials and determined the efficacy of different gums on glycemic indices. Method Systematic search was performed on four main databases (PubMed, Scopus, Embase, Web of Science) by November 2023 using medical subject headings. The meta-analyses were conducted on the findings of the studies of guar gum supplementation on glycemic indices including fasting blood glucose (FBG) and HbA1c (hemoglobinA1c) and systematic review studies include the effect of xanthan gum, arabic gum, bitter almond gum, flaxseed gum, oat gum, gellan gum, locust been gum, tragacanth gum, and karaya gum on fasting plasma insulin, postprandial plasma glucose, HbA1c and Homeostatic Model Assessment for Insulin Resistance (HOMA – IR). Results Totally, 42 studies were included in this systematic review. Regarding guar gum, xanthan gum, and Arabic gum, most of included studies in our investigation showed that guar gum can be considered as an anti-hyperglycemic agent. Results on other types of gums including bitter almond gum, flaxseed gum, oat gum, gellan gum, locust been gum, tragacanth gum, and karaya gum are limited and exact interpretation cannot be obtained. In meta-analysis on 17 studies of guar gum, it was identified guar gum had a non-significant decrease of 3.02 mg/dl (Mean difference: -3.02, CI 95%: -7.60, 1.56) on the fasting glucose and 0.23 (Mean difference: -0.23, CI 95%: -0.63, 0.17) on HbA1c. Conclusion Modification of food processing using gums may be a promising strategy to help modulate glycemic indices. More studies with larger sample size are needed, both with acute and long-term interventions to clarify this issue.
- Open Access
- 9 October 2024
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 24 (1) , 1-15
The effect of glucomannan supplementation on lipid profile in adults: a GRADE-assessed systematic review and meta-analysis
Glucomannan has been studied for various health benefits, but its effects on lipid profile in adults are not well understood. This meta-analysis aims to evaluate the impact of glucomannan supplementation on serum/plasma levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), Apo B1, Apo A1, APO-B/ A1 ratio, and LDL-C/ HDL-C in adults. A comprehensive search was conducted across Scopus, PubMed, Embase, and Web of Science from inception to June 2024 to identify randomized controlled trials (RCTs) assessing glucomannan supplementation on lipid profile in adults. Data were extracted and analyzed using random effects model to determine the standardized mean differences (SMDs) and 95% confidence intervals (CIs) for each biomarker. Glucomannan supplementation significantly decreased TC (SMD: -3.299; 95% CI: -4.955, -1.664, P < 0.001; I 2 = 95.41%, P-heterogeneity < 0.001), LDL-C (SMD: -2.993; 95% CI: -4.958, -1.028; P = 0.006; I 2 = 95.49%, P-heterogeneity < 0.001), and Apo B1 (SMD: -2.2; 95% CI: -3.58, -0.82; P = 0.01). However, glucomannan did not alter the levels of TG (SMD: -0.119; 95% CI: -1.076, 0.837, P = 0.789; I 2 = 91.63%, P-heterogeneity < 0.001), Apo A1 (SMD: -0.48; 95% CI: -6.27, 5.32; P = 0.76), APO-B/ A1 ratio (SMD: -1.15; 95% CI: -2.91, 0.61; P = 0.11), and LDL-C/ HDL-C ratio (SMD: -2.2; 95% CI: -7.28, 2.87; P = 0.2). Glucomannan supplementation has a beneficial effect on the level of TC and LDL-C.
- 9 October 2024
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 24 (1) , 1-15
Open AccessThe effect of glucomannan supplementation on lipid profile in adults: a GRADE-assessed systematic review and meta-analysis
Glucomannan has been studied for various health benefits, but its effects on lipid profile in adults are not well understood. This meta-analysis aims to evaluate the impact of glucomannan supplementation on serum/plasma levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), Apo B1, Apo A1, APO-B/ A1 ratio, and LDL-C/ HDL-C in adults. A comprehensive search was conducted across Scopus, PubMed, Embase, and Web of Science from inception to June 2024 to identify randomized controlled trials (RCTs) assessing glucomannan supplementation on lipid profile in adults. Data were extracted and analyzed using random effects model to determine the standardized mean differences (SMDs) and 95% confidence intervals (CIs) for each biomarker. Glucomannan supplementation significantly decreased TC (SMD: -3.299; 95% CI: -4.955, -1.664, P < 0.001; I 2 = 95.41%, P-heterogeneity < 0.001), LDL-C (SMD: -2.993; 95% CI: -4.958, -1.028; P = 0.006; I 2 = 95.49%, P-heterogeneity < 0.001), and Apo B1 (SMD: -2.2; 95% CI: -3.58, -0.82; P = 0.01). However, glucomannan did not alter the levels of TG (SMD: -0.119; 95% CI: -1.076, 0.837, P = 0.789; I 2 = 91.63%, P-heterogeneity < 0.001), Apo A1 (SMD: -0.48; 95% CI: -6.27, 5.32; P = 0.76), APO-B/ A1 ratio (SMD: -1.15; 95% CI: -2.91, 0.61; P = 0.11), and LDL-C/ HDL-C ratio (SMD: -2.2; 95% CI: -7.28, 2.87; P = 0.2). Glucomannan supplementation has a beneficial effect on the level of TC and LDL-C.
- Open Access
- 9 July 2024
- Published by Elsevier in Complementary Therapies in Medicine
- Vol. 84, 103066
The effects of flaxseed (Linum usitatissimum) supplementation on anthropometric indices: An updated systematic review and meta-analysis of randomized clinical trials
- 9 July 2024
- Published by Elsevier in Complementary Therapies in Medicine
- Vol. 84, 103066
Open AccessThe effects of flaxseed (Linum usitatissimum) supplementation on anthropometric indices: An updated systematic review and meta-analysis of randomized clinical trials
- 1 May 2024
- Published by Bentham Science Publishers Ltd. in Current Rheumatology Reviews
- Vol. 20 (2) , 200-207
An Exploration of Some Predictors of Quality of Life-Related to the Innate Immune System, Inflammation, and Disease Activity in Patients with Behcet's Syndrome: An Analytical Cross-sectional Study
Background: Behçet's disease (BD) has a growing prevalence in Silk Road countries. The aim of our cross-sectional study was to explore the clinical and molecular predictors of quality of life in BD patients. Material and Methods: One hundred and fifty consecutive Iranian BD patients with an age range between 20-50 years were included. The Leeds Behçet's disease quality of life (BDQoL) in Persian form was fulfilled to evaluate the quality of life. Anthropometric measurements were carried out us-ing the calibrated scales. Iranian Behcet's Disease Dynamic Activity Measure (IBDDAM), Behcet's disease current activity form (BDCAF), and Total Inflammatory Activity Index (TIAI) were used to assess BD activity. mRNA expression of toll-like receptors 2 and 4 (TLR2 and TLR4) and tumor-necrosis-factor-alpha (TNF-α) levels in serum were measured by real-time polymerase chain reac-tion (PCR) and ELISA, respectively. Multiple linear backward regression at P = 0.1 was used to study the potential predictors of quality of life. Results: TLR2 and BDCAF were shown to be the most important predictors of quality of life in BD patients by 22%. There were positive associations between them (β = 0.326, p = 0.013 for BDCAF; β = 0.366, p = 0.006 for TLR2) and BDQoL value. Conclusion: Higher TLR2 expression as a key protein in recognizing pathogens by innate immunity and BDCAF value as a comprehensive BD assessing scale contribute to poor quality of life among BD patients. Emphasizing therapeutically, approaches associated with lower TLR2 expression and BDCAF value can be considered in future studies.
- 1 May 2024
- Published by Bentham Science Publishers Ltd. in Current Rheumatology Reviews
- Vol. 20 (2) , 200-207
An Exploration of Some Predictors of Quality of Life-Related to the Innate Immune System, Inflammation, and Disease Activity in Patients with Behcet's Syndrome: An Analytical Cross-sectional Study
Background: Behçet's disease (BD) has a growing prevalence in Silk Road countries. The aim of our cross-sectional study was to explore the clinical and molecular predictors of quality of life in BD patients. Material and Methods: One hundred and fifty consecutive Iranian BD patients with an age range between 20-50 years were included. The Leeds Behçet's disease quality of life (BDQoL) in Persian form was fulfilled to evaluate the quality of life. Anthropometric measurements were carried out us-ing the calibrated scales. Iranian Behcet's Disease Dynamic Activity Measure (IBDDAM), Behcet's disease current activity form (BDCAF), and Total Inflammatory Activity Index (TIAI) were used to assess BD activity. mRNA expression of toll-like receptors 2 and 4 (TLR2 and TLR4) and tumor-necrosis-factor-alpha (TNF-α) levels in serum were measured by real-time polymerase chain reac-tion (PCR) and ELISA, respectively. Multiple linear backward regression at P = 0.1 was used to study the potential predictors of quality of life. Results: TLR2 and BDCAF were shown to be the most important predictors of quality of life in BD patients by 22%. There were positive associations between them (β = 0.326, p = 0.013 for BDCAF; β = 0.366, p = 0.006 for TLR2) and BDQoL value. Conclusion: Higher TLR2 expression as a key protein in recognizing pathogens by innate immunity and BDCAF value as a comprehensive BD assessing scale contribute to poor quality of life among BD patients. Emphasizing therapeutically, approaches associated with lower TLR2 expression and BDCAF value can be considered in future studies.
- 13 January 2024
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 34 (3) , 569-580
A high dietary acid load can potentially exacerbate cardiometabolic risk factors: An updated systematic review and meta-analysis of observational studies
- 13 January 2024
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 34 (3) , 569-580
A high dietary acid load can potentially exacerbate cardiometabolic risk factors: An updated systematic review and meta-analysis of observational studies